Guardant Health (GH)
(Real Time Quote from BATS)
$20.00 USD
+2.04 (11.36%)
Updated Mar 28, 2024 02:48 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Guardant Health (GH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$43.33 | $64.00 | $27.00 | 141.26% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Guardant Health comes to $43.33. The forecasts range from a low of $27.00 to a high of $64.00. The average price target represents an increase of 141.26% from the last closing price of $17.96.
Analyst Price Targets (15)
Broker Rating
Guardant Health currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 19 brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on 19 recommendations.
Of the 19 recommendations deriving the current ABR, 15 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 78.95% and 10.53% of all recommendations. A month ago, Strong Buy made up 78.95%, while Buy represented 10.53%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 15 | 15 | 15 | 15 | 14 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 2 | 2 | 2 | 2 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.29 | 1.29 | 1.21 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/27/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
2/26/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
2/23/2024 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
12/15/2023 | Scotiabank | Sung-Ji Nam | Strong Buy | Strong Buy |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Hold |
11/13/2023 | Raymond James | Andrew Cooper | Hold | Moderate Buy |
11/7/2023 | William Blair | Andrew F Brackmann | Strong Buy | Strong Buy |
11/6/2023 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 19 |
Average Target Price | $43.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 252 |
Current Quarter EPS Est: | -0.94 |